


# New Drug Pipeline chapter (powered by Cortellis)

## Disease Landscape & Forecast

Drug Pipeline adds real-time pipeline intelligence to the Disease Landscape & Forecast, helping you fully assess market opportunities and competitive threats within a disease space. All content in the Drug Pipeline chapter comes directly from Cortellis Competitive Intelligence and is refreshed daily.

The Drug Pipeline content is available for fifty-nine diseases (refer to appendix for list)

1. Select **Drug Pipeline** from the Disease **Landscape & Forecast** table of contents.



2. Three **pipeline overview figures** are displayed first.

- 1) Number of drugs in clinical development
- 2) Number of companies with drugs in clinical development
- 3) Number of terminated drugs.




Where applicable, the figures are segmented by the associated Cortellis indications, accessible via a drop-down menu. The first two figures are broken down by clinical phase – Phase 1, Phase 2, Phase 3, or Clinical (if the specific phase is undisclosed). The third figure shows the phase the drug was in when terminated and is broken down by clinical phases, Preclinical, Discovery, Pre-registration, and Registered.

For reports with more than one associated Cortellis indication, select the indication of interest from the dropdown menu.

Select **Download Data** to download corresponding data table and select Download chart to download corresponding figure.

**Hover** over donut slice to view number figure.

Click here to be **redirected to Cortellis Competitive Intelligence** to view full drug list for the disease.



3. Underneath the charts you will find the **pipeline table**, giving you the full list of drugs in active clinical development for the disease, inclusive of all associated Cortellis indications. The table includes detailed information about each drug (such as companies, highest status, targets and more) and can be customized and downloaded.

Use **Download Data** to download the full pipeline table to Excel

Click on the down arrow to **filter** the list of drugs (available for Drug name, Active companies, Active indications, Highest status, Target-based action and Regulatory designation)

Click on:

- 1 - Expand table to view more columns without scrolling,
- 2 - Save table to save changes, and
- 3 - Restore to default to return to original view.

Drugs in active clinical development for non small cell lung cancer

Download Data | Restore to default | View saved table | Save table | Expand table

Drug name	Other drug names	Originator company	Active companies	Active indications	Highest status	Target-based action	Technologies
[18F]-AraG (cancer), CellSight	[18F]-AraG; fluorine-18-F-AraG	CellSight Technology, Inc.	CellSight Technology, Inc.; University of California San Francisco; Stanford University	Coronavirus disease 19 infection; HIV infection; Bladder cancer; Squamous cell carcinoma; Non-Hodgkin lymphoma; Metastatic non small cell lung cancer; Advanced solid tumor; Graft versus host disease; Head and neck tumor; Cancer	Phase 2 Clinical		Small molecule therapy; formulation; Radiolabeling
18F-LY3546117	18F-LY3546117	Avid Radiopharmaceuticals Inc.	Avid Radiopharmaceuticals Inc.	Non-small-cell lung cancer; Melanoma; Cancer	Phase 1 Clinical	Granzyme B modulator	Small molecule therapy; formulation; Radiolabeling
18F-ODS-2004436	18F-ODS-2004436; Fluorine-18-ODS-2004436; ODS-2004436-(18F)	Oncodesign Biotechnology SA	Oncodesign Biotechnology SA; Laboratoires Cytelpharma	Non-small-cell lung cancer	Phase 1 Clinical		Radiolabeling; System unspecified; Small molecule
64Cu-DOTA-nivolumab		Ono Pharmaceutical Co Ltd	Ono Pharmaceutical Co Ltd; Bristol Myers Squibb Co	Stage IV melanoma; Metastatic non small cell lung cancer	Clinical	Programmed cell death protein 1 inhibitor	Immunology; Biotechnology; Radiolabeling; Immunotherapy; Parenteral formulation
68Ga-NeobOMB1		Erasmus University Medical Center Rotterdam	Advanced Accelerator Applications SA	Small-cell lung cancer; Non-small-cell lung cancer; Prostate tumor; Gastrointestinal stromal tumor; Advanced solid tumor; Breast tumor; Colorectal tumor	Phase 2 Clinical	Bombesin 882 receptor antagonist	Radiolabeling; Intravenous; Peptide
68Ga-NOTA-hGZP		Massachusetts General Hospital	Cytosize Biopharma Inc.	Stage IV melanoma; Metastatic non small cell lung cancer	Phase 1 Clinical		Biological therapy; Parenteral formulation
89Zr-APOMAB	89Zr-APOMAB	Central Adelaide Local Health Network Inc.	Central Adelaide Local Health Network Inc.	Small-cell lung cancer; Metastatic non small cell lung cancer; Metastatic ovarian cancer	Phase 1 Clinical		Humanized antibody; formulation unspecified; Radiolabeling; Humoral
89Zr-Df-IAB-22M2C	IAB-2223M1; IAB-22M2C; 89Zr-Df-IAB-22M2C	ImaginAb Inc.	Torrey Capital LLC	Merkel cell carcinoma; Stage IV melanoma; Metastatic non small cell lung cancer	Phase 2 Clinical	T-cell surface glycoprotein	Radiolabeling; Humoral; Fragment; Monoclonal antibody

Drug records: 677

Source: Cortellis Competitive Intelligence. Drugs included in this table are in active clinical development for non small cell lung cancer, meaning that their current status is Phase 1 Clinical, Phase 2 Clinical, Phase 3 Clinical, or Clinical (unspecified phase) for non small cell lung cancer. Drugs excluded from this table have a current status of launched, registered, pre-registered, preclinical, or discovery for non small cell lung cancer. Drugs that are suspended, withdrawn, or have no development reported for non small cell lung cancer are also excluded.

[Click here to view full pipeline in Cortellis Competitive Intelligence](#)


Click on a column header to **sort** the table (available for Drug name, Originator company, Highest status and Clinical trials). Drag and drop column headers to **change column order**.

Click on the **Columns** icon to add/remove columns displayed in the table.


4. Scroll down to the **Regulatory Milestones** section, which gives you a timeline view of the drugs that have been granted regulatory designations for the disease. This figure expands report content by displaying additional indications (beyond the report indication) in which these drugs are being investigated. These dynamic timelines allow you to compare drugs in a time sequence to better understand time to market and the regulatory landscape for the disease.

The timeline can be filtered to specific drugs, regulatory milestones, indications, or regions of interest. Raw data can be downloaded to Excel, including the date and status of each regulatory milestone.

Please note that the regulatory milestones are for the G7 regions only.




5. Indication Comparison - This section allows you to compare clinical trial phasing across all relevant indications for up to 10 drugs at a time on a heatmap.



6. More information regarding the available **Drug Pipeline reports** is available by selecting the “?” link at the bottom right-hand corner of the screen.

Here you will find a link to provide feedback on the Drug Pipeline feature; we welcome your thoughts.



**Resources & updates**

- Product updates
- Contact us
- Guided tours
- Training resources
- Suggest a feature

**Stay up-to-date on drugs of interest with Drug Pipeline**  
Powered by Cortellis

Access real-time, global pipeline intelligence in your Disease Landscape & Forecast report. This content is refreshed daily and comes directly from Cortellis Competitive Intelligence.

Use it today to support your competitive intelligence needs!

**Go to Drug Pipeline**

Link to Drug Pipeline

**Contact us**

Need some help? Our customer care team is here to assist you.

**Ask a question**

**Subject**

Feedback or Feature Request

**Your message**

Type your message in here

☐ This is urgent

☐ Please follow up with me by phone

**Cancel** **Send**

We always value your feedback on this enhancement or any product features. Select 'Contact us' link to provide feedback on Drug Pipeline chapter

## Appendix:

### A. List of diseases for final release:

Acute Myeloid Leukemia	Multiple Sclerosis
Alopecia	Muscular Dystrophy
Alzheimer's Disease	Myelodysplastic Syndromes
Amyotrophic Lateral Sclerosis	Myelofibrosis
Asthma	Non-alcoholic Steatohepatitis
Atopic Dermatitis/Atopic Eczema	Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
Axial Spondylarthritis	Non-Small-Cell Lung Cancer
Beta-Thalassemia	Obesity/Overweight
Bladder Cancer	Osteoporosis
Breast Cancer	Ovarian Cancer
Chronic Kidney Disease	Pancreatic Cancer
Chronic Obstructive Pulmonary Disease	Parkinson's Disease
Colorectal Cancer	Polycystic Kidney Disease
Crohn's Disease	Prostate Cancer
Cystic Fibrosis	Psoriasis
Diabetic Macular Edema / Diabetic Retinopathy	Psoriatic Arthritis
Diabetic Nephropathy	Pulmonary Hypertension
Dry and Wet Age-Related Macular Degeneration	Renal Cell Carcinoma
Endometrial Cancer	Rheumatoid Arthritis
Epilepsy	Schizophrenia
Gastroesophageal Cancer	Scleroderma (Systemic Sclerosis)
Heart Failure	Sickle Cell Disease
Hemophilia	Sjogren's Syndrome
Hepatocellular Carcinoma	Spinal Muscular Atrophy
Idiopathic Pulmonary Fibrosis	Systemic Lupus Erythematosus
IgA Nephropathy	Type 1 Diabetes
Malignant Melanoma	Type 2 Diabetes
Migraine	Ulcerative Colitis
Multiple Myeloma	Unipolar Depression
	Urticaria

## **B. Drug Pipeline Chapter Inclusion Criteria**

### **a. Pipeline Donut Charts (Number of Drugs and Number of Companies) and Pipeline Table**

Drugs included in this table are in active clinical development *for the report indication*, meaning that their current status is Phase 1 Clinical, Phase 2 Clinical, Phase 3 Clinical, or Clinical (unspecified phase) *for the report indication*. Drugs *excluded* from this table have a current status of launched, registered, pre-registered, preclinical, or discovery *for the report indication*. Drugs that are suspended, withdrawn, or have no development reported for the report indication are also *excluded*.

### **b. Regulatory Milestones**

Drugs included in this figure have a granted or planned regulatory designation for the report indication/disease area. Drug must be in active development, launched, registered, or pre-registered. Drugs that are withdrawn, suspended, discontinued, or no development has been reported are excluded.

## **C. Glossary**

- a. Drug Name - The main name for the drug is displayed; this is usually the INN (International Non-proprietary Name).
- b. Other Drug Names - BAN, INN, PINN, USAN, pUSAN, or Trade Name
- c. Originator Company - The company that originated the drug, which is not necessarily the company that is actively developing the drug. This classification is editorially assigned.
- d. Active Company - A company is classified as 'active' if the development status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched or Suspended.
- e. Active Indications - An indication is classified as active if it features on a row (or rows) in the current table where the development status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase II, Pre-registration, Registered, Launched, or Suspended.
- f. Highest Status - The single highest development status associated with the drug (for any indication, in any country/territory, for any company). The highest development status is assigned according to a predefined order, which is (from highest to lowest); Launched, Registered, Pre-registration, Phase 3 Clinical, Phase 2 Clinical, Phase 1 Clinical, Clinical, Discovery, Suspended, Withdrawn, Discontinued, No Development Reported or Outlicensed.
- g. Target-based Action - A target-based action is one that is associated with a target. Each drug is also indexed with ancestor terms for actions to aid searching.
- h. Technologies - Technology terms associated with the drug.
- i. Regulatory Designation - Regulatory designation(s) associated with the drug (for any indication, in any country/territory, for any company).
  - i. Accelerated Approval
  - ii. Advanced Therapy Medicinal Product
  - iii. Animal Rule
  - iv. Breakthrough Therapy
  - v. Clinically Urgent Foreign Drug
  - vi. Emergency Use Authorization
  - vii. Fast Track
  - viii. National Science and Technology Major Project



- ix. New Active Substance
  - x. Orphan Drug
  - xi. Paediatric Investigation Plan
  - xii. PRIME
  - xiii. Priority Review
  - xiv. Promising Innovative Medicine
  - xv. Qualified Infectious Disease Product
  - xvi. Rare Pediatric Disease
  - xvii. Regenerative Medicine Advanced Therapy
  - xviii. Sakigake
  - xix. Special Review Project
  - xx. Tropical Disease Priority Review
- j. Clinical Trials (ongoing) - includes trials where the recruitment status is Recruiting, Not yet recruiting, No longer recruiting, Suspended, or Status not specified.
- k. Clinical Trials (total) - includes all trials linked to the drug, regardless of recruitment status. Trial counts for the drug are based on where the drug is the primary intervention only.

For more information contact Customer Care at [DRG.support@clarivate.com](mailto:DRG.support@clarivate.com).

Clarivate™ is a global leader in providing solutions to accelerate the lifecycle of innovation. Our bold mission is to help customers solve some of the world's most complex problems by providing actionable information and insights that reduce the time from new ideas to life-changing inventions in the areas of science and intellectual property. We help customers discover, protect and commercialize their inventions using our trusted subscription and technology-based solutions coupled with deep domain expertise. For more information, please visit [clarivate.com](https://clarivate.com).